Display options
Cite
Crane JL, Zhao L, Frye JS, et al. IGF-1 Signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass. Bone Res. 2013;1(2):186-94doi: 10.4248/BR201302007.
Crane, J. L., Zhao, L., Frye, J. S., Xian, L., Qiu, T., & Cao, X. (2013). IGF-1 Signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass. Bone research, 1(2), 186-94. https://doi.org/10.4248/BR201302007
Crane, Janet L, et al. "IGF-1 Signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass." Bone research vol. 1,2 (2013): 186-94. doi: https://doi.org/10.4248/BR201302007
Crane JL, Zhao L, Frye JS, Xian L, Qiu T, Cao X. IGF-1 Signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass. Bone Res. 2013 Jun 28;1(2):186-94. doi: 10.4248/BR201302007. eCollection 2013 Jun. PMID: 26273502; PMCID: PMC4472101.
Copy Download .nbib Format: NLM
Share it on

Bone Res. 2013 Jun 28;1(2):186-94. doi: 10.4248/BR201302007. eCollection 2013 Jun.

IGF-1 Signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass.

Bone research

Janet L Crane, Luo Zhao, Joseph S Frye, Lingling Xian, Tao Qiu, Xu Cao

Affiliations

  1. Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, MD 21205, USA ; Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine , Baltimore. MD 21205, USA.
  2. Department of Orthopedics, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences , Beijing. 100730, P.R. China.
  3. University of Missouri School of Medicine , Columbia, MO, 65211, USA.
  4. Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine , Baltimore. MD 21205, USA.

PMID: 26273502 PMCID: PMC4472101 DOI: 10.4248/BR201302007

Abstract

Survival of children with chronic medical illnesses is leading to an increase in secondary osteoporosis due to impaired peak bone mass (PBM). Insulin-like growth factor type 1 (IGF-1) levels correlate with the pattern of bone mass accrual and many chronic illnesses are associated with low IGF-1 levels. Reduced serum levels of IGF-1 minimally affect the integrity of the skeleton, whereas recent studies suggest that skeletal IGF-I regulates PBM. To determine the role of IGF-1 in postnatal bone mass accrual regardless of source, we established an inducible type 1 Igf receptor Cre/lox knockout mouse model, in which the type 1 Igf receptor was deleted inducibely in the mesenchymal stem cells (MSCs) from 3-7 weeks of age. The size of the mouse was not affected as knockout and wild type mice had similar body weights and nasoanal and femoral lengths. However, bone volume and trabecular bone thickness were decreased in the secondary spongiosa of female knockout mice relative to wild type controls, indicating that IGF-1 is critical for bone mass. IGF-1 signaling in MSCs in vitro has been implicated to be involved in both migration to the bone surface and differentiation into bone forming osteoblasts. To clarify the exact role of IGF-1 in bone, we found by immunohistochemical analysis that a similar number of Osterix-positive osteoprogenitors were on the bone perimeter, indicating migration of MSCs was not affected. Most importantly, 56% fewer osteocalcin-positive mature osteoblasts were present on the bone perimeter in the secondary spongiosa in knockout mice versus wild type littermates. These in vivo data demonstrate that the primary role of skeletal IGF-1 is for the terminal differentiation of osteoprogenitors, but refute the role of IGF-1 in MSC migration in vivo. Additionally, these findings confirm that impaired IGF-1 signaling in bone MSCs is sufficient to impair bone mass acquisition.

Keywords: IGF receptor; cell migration; knockout mice; nestin; osteoblasts

References

  1. Br J Orthod. 1998 May;25(2):101-7 - PubMed
  2. Cell Stem Cell. 2012 Mar 2;10(3):259-72 - PubMed
  3. Endocr Rev. 2009 Aug;30(5):494-535 - PubMed
  4. Bone. 2008 Nov;43(5):869-79 - PubMed
  5. Science. 2000 Sep 1;289(5484):1504-8 - PubMed
  6. Cell Mol Life Sci. 2004 Oct;61(19-20):2510-22 - PubMed
  7. N Engl J Med. 2005 May 12;352(19):2014-6 - PubMed
  8. Crit Rev Eukaryot Gene Expr. 2009;19(1):73-88 - PubMed
  9. Endocr Dev. 2005;9:11-6 - PubMed
  10. Endocrinology. 2000 Jul;141(7):2674-82 - PubMed
  11. J Bone Miner Res. 2011 Apr;26(4):865-72 - PubMed
  12. Cell Stem Cell. 2010 Nov 5;7(5):571-80 - PubMed
  13. Nature. 2010 Aug 12;466(7308):829-34 - PubMed
  14. Nat Med. 2007 Jul;13(7):791-801 - PubMed
  15. J Endocrinol Invest. 2005;28(8 Suppl):32-6 - PubMed
  16. Endocr Rev. 2008 Aug;29(5):535-59 - PubMed
  17. J Vet Sci. 2011 Mar;12(1):1-6 - PubMed
  18. Endocr Rev. 2009 Oct;30(6):586-623 - PubMed
  19. J Biol Chem. 2002 Nov 15;277(46):44005-12 - PubMed
  20. J Am Acad Nurse Pract. 2004 Jul;16(7):274-82 - PubMed
  21. Nat Med. 2011 Oct 23;17(11):1473-80 - PubMed
  22. Bone. 2010 Feb;46(2):294-305 - PubMed
  23. Nat Med. 2009 Jul;15(7):757-65 - PubMed
  24. Biochem Biophys Res Commun. 2007 May 11;356(3):780-4 - PubMed
  25. Best Pract Res Clin Rheumatol. 2005 Dec;19(6):991-1005 - PubMed
  26. J Clin Endocrinol Metab. 1996 Jan;81(1):44-8 - PubMed
  27. J Clin Endocrinol Metab. 1998 Jul;83(7):2331-7 - PubMed
  28. BMC Neurosci. 2011 Jun 30;12:64 - PubMed
  29. Nat Med. 2012 Jul;18(7):1095-101 - PubMed
  30. Cell. 2011 Jun 24;145(7):1142-55 - PubMed
  31. Science. 2003 Dec 5;302(5651):1704-9 - PubMed
  32. J Bone Miner Res. 2007 Jun;22(6):799-807 - PubMed
  33. J Bone Miner Metab. 2008;26(2):159-64 - PubMed
  34. Calcif Tissue Int. 2006 Jan;78(1):18-24 - PubMed

Publication Types

Grant support